Related references
Note: Only part of the references are listed.Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
Laetitia Dahan et al.
GUT (2010)
Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer
Anna Novarino et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
C. Yoo et al.
BRITISH JOURNAL OF CANCER (2009)
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
Seong Yoon Yi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study
Brett E. Fortune et al.
ONCOLOGY (2009)
Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study
Uwe Pelzer et al.
ONKOLOGIE (2009)
Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-line Therapy for Patients With Advanced Pancreatic Cancer
Henry Q. Xiong et al.
CANCER (2008)
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer
L. S. Blaszkowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
Volker Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
M Reni et al.
BRITISH JOURNAL OF CANCER (2006)
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
A Demols et al.
BRITISH JOURNAL OF CANCER (2006)
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
N Tsavaris et al.
INVESTIGATIONAL NEW DRUGS (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer -: A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer Study
T Conroy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
CMR Lima et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer
M Cantore et al.
ONCOLOGY (2004)
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
H Ulrich-Pur et al.
BRITISH JOURNAL OF CANCER (2003)
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial
W Scheithauer et al.
ANNALS OF ONCOLOGY (2003)
EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary
M. Sant et al.
ANNALS OF ONCOLOGY (2003)
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
JD Berlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
SR Bramhall et al.
BRITISH JOURNAL OF CANCER (2002)
Present and future treatment of pancreatic cancer
V Heinemann
SEMINARS IN ONCOLOGY (2002)
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma - A prospective, randomized phase III study of the Gruppo Oncologico dell'Italia Meridionale
G Colucci et al.
CANCER (2002)
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer
P Kozuch et al.
ONCOLOGIST (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
H Oettle et al.
ANTI-CANCER DRUGS (2000)